Dopiopharm – Ihr Partner für pharmazeutische Exzellenz und Cannabislösungen

Your Partner in Pharmaceutical Excellence and Premium Cannabis Products

Our story

Committed to Quality and Expertise Since Day One

Established in 2018, Dopiopharm was founded with a clear mission: to obtain all necessary licenses for distributing medicinal products for pain management under the rigorous requirements of the German Narcotics Act. From the outset, we identified the challenges of implementing a robust quality management system and appointing key roles (e.g., the Qualified Person for Narcotics in acc. with § 5 BtMG or the Responsible Person for Wholesale in acc. with § 52a AMG).
This hands-on experience led to the creation of a bespoke service offering, enabling us to share our expertise with clients while maintaining a commitment to the highest standards in pharmaceutical quality management.
From this experience, the idea was born to share our expertise through a tailored service offering.

Our expertise: Quality management at the highest level

Dopiopharm was founded in 2018 with a clear mission: to secure all necessary licenses for the distribution of pain management pharmaceuticals that are subject to the stringent requirements of the Narcotics Act.Even at that early stage, we identified the challenges involved in implementing a comprehensive quality management system and appointing key responsible roles, such as the Qualified Person for narcotics handling in accordance with § 5 BtMG or the Responsible Person for wholesale activities under § 52a AMG.
This experience inspired the development of a tailored service offering, allowing us to share our expertise with others.

A New Milestone in 2023

In 2023, under the visionary leadership of Ms. Klotzbach-Bierhoff, Dopiopharm entered an exciting new chapter. With fresh entrepreneurial energy and a clear vision, the company expanded its focus to include the development and distribution of proprietary cannabis-based products and pain medications.
This strategic pivot not only broadens opportunities for our customers and partners but also underlines our dedication to innovation, quality and sustainability in all aspects of our operations.

More about the company

Tikun Cannabis Products by Dopiopharm

Pioneeringin Medical Cannabis with Scientific Evidence

Founded in Israel in 2005, Tikun Olam is a global leader in the research and development of medical cannabis. From the very beginning, the company has consistently partnered with leading scientists and universities to conduct extensive studies and drive advancements in medical cannabis applications.
For the German market, Dopiopharm has forged an exclusive partnership with Tikun Olam to offer premium, scientifically backed cannabis products.

For the German market, we have established an exclusive partnership with Tikun Olam Europe to offer our customers premium-quality products.

Cannabis from Greece

A New High-Tech Standard in Cultivation

Tikun Olam's ultra-modern facility in Greece began operations in 2022 and is among the most advanced cannabis production sites in the world.

Spanning an impressive 56,000 m², the facility is both GACP and EU-GMP certified, ensuring compliance with the highest standards in cannabis cultivation and processing.